Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ProQR Therapeutics

Nasdaq:PRQR
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PRQR
Nasdaq
$357M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • ProQR Therapeutics has significant price volatility in the past 3 months.
PRQR Share Price and Events
7 Day Returns
34.2%
NasdaqGM:PRQR
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-48.2%
NasdaqGM:PRQR
1.6%
US Biotechs
-9.1%
US Market
PRQR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ProQR Therapeutics (PRQR) 34.2% 4.1% -23.7% -48.2% 43.6% -65%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • PRQR underperformed the Biotechs industry which returned 1.6% over the past year.
  • PRQR underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
PRQR
Industry
5yr Volatility vs Market

Value

 Is ProQR Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ProQR Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ProQR Therapeutics.

NasdaqGM:PRQR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:PRQR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.203 (1 + (1- 25%) (4.21%))
1.161
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.16
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.161 * 5.44%)
8.06%

Discounted Cash Flow Calculation for NasdaqGM:PRQR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ProQR Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:PRQR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.06%)
2020 -65.56 Analyst x3 -60.67
2021 -87.35 Analyst x3 -74.81
2022 -69.30 Analyst x3 -54.93
2023 -3.71 Analyst x3 -2.72
2024 92.67 Analyst x3 62.90
2025 155.25 Est @ 67.54% 97.53
2026 229.47 Est @ 47.8% 133.40
2027 307.44 Est @ 33.98% 165.41
2028 382.18 Est @ 24.31% 190.28
2029 449.22 Est @ 17.54% 206.98
Present value of next 10 years cash flows €663.00
NasdaqGM:PRQR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €449.22 × (1 + 1.74%) ÷ (8.06% – 1.74%)
€7,235.18
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €7,235.18 ÷ (1 + 8.06%)10
€3,333.71
NasdaqGM:PRQR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €663.00 + €3,333.71
€3,996.71
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €3,996.71 / 49.75
€80.34
NasdaqGM:PRQR Discount to Share Price
Calculation Result
Exchange Rate EUR/USD
(Reporting currency to currency of NasdaqGM:PRQR)
1.109
Value per Share
(USD)
= Value per Share in EUR x Exchange Rate (EUR/USD)
= €80.34 x 1.109
$89.08
Value per share (USD) From above. $89.08
Current discount Discount to share price of $7.18
= -1 x ($7.18 - $89.08) / $89.08
91.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ProQR Therapeutics is available for.
Intrinsic value
>50%
Share price is $7.18 vs Future cash flow value of $89.08
Current Discount Checks
For ProQR Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ProQR Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ProQR Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ProQR Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ProQR Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:PRQR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-1.38
NasdaqGM:PRQR Share Price ** NasdaqGM (2020-03-27) in USD $7.18
NasdaqGM:PRQR Share Price converted to EUR reporting currency Exchange rate (USD/ EUR) 0.902 €6.48
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ProQR Therapeutics.

NasdaqGM:PRQR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:PRQR Share Price ÷ EPS (both in EUR)

= 6.48 ÷ -1.38

-4.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ProQR Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • ProQR Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does ProQR Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:PRQR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
22.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ProQR Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ProQR Therapeutics's assets?
Raw Data
NasdaqGM:PRQR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €1.90
NasdaqGM:PRQR Share Price * NasdaqGM (2020-03-27) in USD $7.18
NasdaqGM:PRQR Share Price converted to EUR reporting currency Exchange rate (USD/ EUR) 0.902 €6.48
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:PRQR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:PRQR Share Price ÷ Book Value per Share (both in EUR)

= 6.48 ÷ 1.90

3.42x

* Primary Listing of ProQR Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ProQR Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess ProQR Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ProQR Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ProQR Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ProQR Therapeutics expected to grow at an attractive rate?
  • ProQR Therapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • ProQR Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • ProQR Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:PRQR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:PRQR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 22.9%
NasdaqGM:PRQR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 62.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:PRQR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:PRQR Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 240 259 39 4
2023-12-31 119 103 -42 4
2022-12-31 45 -49 -90 4
2021-12-31 7 -120 -102 5
2020-12-31 1 -59 -73 6
2020-03-28
NasdaqGM:PRQR Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 2 -44 -56
2019-09-30 3 -41 -51
2019-06-30 5 -37 -45
2019-03-31 6 -31 -40
2018-12-31 6 -28 -37
2018-09-30 4 -28 -35
2018-06-30 2 -31 -40
2018-03-31 1 -36 -44
2017-12-31 1 -35 -44
2017-09-30 1 -34 -41
2017-06-30 1 -37 -41
2017-03-31 1 -35 -39

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ProQR Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • ProQR Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:PRQR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from ProQR Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PRQR Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.71 3.19 -0.82 4.00
2023-12-31 -0.63 0.80 -1.48 4.00
2022-12-31 -1.51 -1.13 -1.72 4.00
2021-12-31 -1.97 -1.29 -2.74 5.00
2020-12-31 -1.46 -1.20 -1.81 5.00
2020-03-28
NasdaqGM:PRQR Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -1.38
2019-09-30 -1.31
2019-06-30 -1.19
2019-03-31 -1.13
2018-12-31 -1.08
2018-09-30 -1.12
2018-06-30 -1.35
2018-03-31 -1.59
2017-12-31 -1.72
2017-09-30 -1.71
2017-06-30 -1.73
2017-03-31 -1.68

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ProQR Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ProQR Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ProQR Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ProQR Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ProQR Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ProQR Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ProQR Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ProQR Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ProQR Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ProQR Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PRQR Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1.93 -56.48 12.89 46.49
2019-09-30 2.67 -50.87 13.57 42.10
2019-06-30 5.10 -44.69 13.25 37.33
2019-03-31 5.50 -40.39 13.02 33.79
2018-12-31 5.59 -36.89 12.50 29.51
2018-09-30 4.31 -35.26 10.79 28.32
2018-06-30 1.68 -39.81 10.97 29.25
2018-03-31 1.10 -43.82 11.21 30.81
2017-12-31 0.87 -43.64 10.84 31.15
2017-09-30 0.89 -41.17 10.21 30.91
2017-06-30 1.01 -40.79 9.46 32.00
2017-03-31 1.26 -39.39 9.18 33.06
2016-12-31 1.63 -39.10 9.48 31.92
2016-09-30 2.64 -36.41 9.22 30.32
2016-06-30 3.38 -32.60 8.67 28.00
2016-03-31 3.49 -31.27 7.84 24.82
2015-12-31 3.19 -20.83 6.84 23.40
2015-09-30 2.59 -16.74 6.84 20.18
2015-06-30 1.40 -13.80 7.76 16.64
2015-03-31 0.65 -9.97 7.52 14.48
2014-12-31 0.31 -12.13 6.51 10.27
2014-09-30 0.00 -11.72 4.86 8.26
2014-06-30 0.00 -9.23 2.67 6.49
2014-03-31 0.06 -4.80 1.26 3.53
2013-12-31 0.12 -3.25 0.79 2.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ProQR Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ProQR Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ProQR Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ProQR Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ProQR Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ProQR Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ProQR Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ProQR Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ProQR Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ProQR Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 9.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ProQR Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:PRQR Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 93.83 13.05 111.95
2019-09-30 59.42 10.77 74.79
2019-06-30 70.23 10.54 82.46
2019-03-31 80.81 10.30 94.08
2018-12-31 92.69 9.39 105.58
2018-09-30 102.40 8.33 113.72
2018-06-30 22.73 8.02 32.97
2018-03-31 29.45 7.73 38.00
2017-12-31 39.33 7.24 48.10
2017-09-30 32.74 6.48 39.74
2017-06-30 36.78 6.09 42.32
2017-03-31 45.74 5.84 52.11
2016-12-31 53.14 5.70 59.20
2016-09-30 61.43 5.39 64.92
2016-06-30 70.93 5.27 76.31
2016-03-31 80.20 5.14 85.47
2015-12-31 89.80 4.82 94.87
2015-09-30 95.63 4.33 100.01
2015-06-30 101.64 4.23 106.38
2015-03-31 109.93 2.89 113.82
2014-12-31 109.40 2.81 112.74
2014-09-30 111.20 2.75 115.26
2014-06-30 34.02 2.68 38.19
2014-03-31 -0.09 3.54 4.13
2013-12-31 -0.09 3.46 4.13
  • ProQR Therapeutics's level of debt (13.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (2.6% vs 13.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ProQR Therapeutics has sufficient cash runway for 2.5 years based on current free cash flow.
  • ProQR Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 19.6% each year.
X
Financial health checks
We assess ProQR Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ProQR Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ProQR Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ProQR Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of ProQR Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ProQR Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ProQR Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:PRQR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:PRQR Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ProQR Therapeutics has not reported any payouts.
  • Unable to verify if ProQR Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ProQR Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ProQR Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ProQR Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess ProQR Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ProQR Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ProQR Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ProQR Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Daniel de Boer
COMPENSATION €1,403,000
AGE 36
TENURE AS CEO 8.1 years
CEO Bio

Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. Mr. de Boer is responsible for the overall strategy and general business at ProQR Therapeutics. He is a passionate and driven entrepreneur and advocate for CF patients and has assembled an experienced team of successful biotech executives as co-founders and early investors. He is a serial entrepreneur in IT, he founded and led a number of tech companies through phases of growth, initiating development and launch of several IT related products in several European countries. He served as a founder and Chief Executive Officer of RNA Systems from 2009 to 2011. From 2007 to 2008, he was Founder and Chief Executive Officer of PC Basic and from 2005 to 2011, he served as a Founder and Chief Executive Officer of Running IT.

CEO Compensation
  • Daniel's compensation has increased whilst company is loss making.
  • Daniel's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the ProQR Therapeutics management team in years:

2.4
Average Tenure
49
Average Age
  • The tenure for the ProQR Therapeutics management team is about average.
Management Team

Daniel de Boer

TITLE
CEO & Member of Management Board
COMPENSATION
€1M
AGE
36
TENURE
8.1 yrs

Smital Shah

TITLE
Chief Business & Financial Officer
AGE
43
TENURE
5.4 yrs

Lisa Hayes

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
1.3 yrs

Bart Klein

TITLE
Senior Vice President of Intellectual Property

Gerard Platenburg

TITLE
Chief Innovation Officer & Chairman of Advisory Board
COMPENSATION
€34K
AGE
55
TENURE
6.1 yrs

Bianca Matthee

TITLE
Head of Manufacturing and Pharmaceutics

David Rodman

TITLE
Executive Vice President of Research & Development
AGE
64

Pete Adamson

TITLE
Senior Vice President of Ophthalmology Franchise
TENURE
2.4 yrs

Aniz Girach

TITLE
Chief Medical Officer
TENURE
1.3 yrs

Tiffany Burt

TITLE
Head of Commercial & VP
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the ProQR Therapeutics board of directors in years:

2.8
Average Tenure
63
Average Age
  • The average tenure for the ProQR Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Dinko Valerio

TITLE
Chairman of Supervisory Board
COMPENSATION
€105K
AGE
63

Gerard Platenburg

TITLE
Chief Innovation Officer & Chairman of Advisory Board
COMPENSATION
€34K
AGE
55
TENURE
2.6 yrs

James Shannon

TITLE
Member of Supervisory Board
COMPENSATION
€106K
AGE
63
TENURE
3.8 yrs

Antoine Papiernik-Berkhauer

TITLE
Member of Supervisory Board
COMPENSATION
€72K
AGE
53
TENURE
6.2 yrs

Art Levin

TITLE
Member of Scientific Advisory Board
AGE
65

Alison Lawton

TITLE
Member of Supervisory Board
COMPENSATION
€106K
AGE
58
TENURE
5.5 yrs

Phil Zamore

TITLE
Member of Scientific Advisory Board
TENURE
2.8 yrs

Cy Stein

TITLE
Member of Scientific Advisory Board
AGE
66
TENURE
2.8 yrs

Annemieke Rus

TITLE
Member of Scientific Advisory Board
TENURE
2.8 yrs

Ted Dryja

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess ProQR Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ProQR Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

NasdaqGM:PRQR Historical Debt, August 15th 2019 A Look At ProQR Therapeutics's Liabilities According to the last reported balance sheet, ProQR Therapeutics had liabilities of €9.05m due within 12 months, and liabilities of €11.0m due beyond 12 months. … But it is future earnings, more than anything, that will determine ProQR Therapeutics's ability to maintain a healthy balance sheet going forward. … Overall, its balance sheet doesn't seem overly risky, at the moment, but we're always cautious until we see the positive free cash flow.

Simply Wall St -

What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year?

See our latest analysis for ProQR Therapeutics How Does Daniel de Boer's Compensation Compare With Similar Sized Companies? … Boasting a total shareholder return of 87% over three years, ProQR Therapeutics N.V. … CEO compensation is one thing, but it is also interesting to check if the CEO is buying or selling ProQR Therapeutics (free visualization of insider trades).

Simply Wall St -

The ProQR Therapeutics (NASDAQ:PRQR) Share Price Has Gained 163%, So Why Not Pay It Some Attention?

View our latest analysis for ProQR Therapeutics Because ProQR Therapeutics is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … ProQR Therapeutics's revenue trended up 25% each year over three years. … You could get a better understanding of ProQR Therapeutics's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Simply Wall St -

Is ProQR Therapeutics N.V. (NASDAQ:PRQR) Overpaying Its CEO?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Daniel de Boer's Compensation Compare With Similar Sized Companies. … is worth US$555m, and total annual CEO compensation is €1.2m.

Simply Wall St -

Before You Buy ProQR Therapeutics N.V. (NASDAQ:PRQR), Consider Its Volatility

(NASDAQ:PRQR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility).

Simply Wall St -

Who Really Owns ProQR Therapeutics NV (NASDAQ:PRQR)?

In this article, I will take a quick look at ProQR Therapeutics NV’s (NASDAQ:PRQR) recent ownership structure – an unconventional investing subject, but an important one. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Should You Be Concerned With ProQR Therapeutics NV.'s (NASDAQ:PRQR) -11.25% Earnings Drop?

Check out our latest analysis for ProQR Therapeutics Was PRQR's recent earnings decline worse than the long-term trend and the industry? … For ProQR Therapeutics, its most recent earnings (trailing twelve month) is -€43.82M, which, relative to the previous year's figure, has become more negative. … ProQR Therapeutics's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story.

Simply Wall St -

Does ProQR Therapeutics NV's (NASDAQ:PRQR) -9.9% Earnings Decline Reflect A Long-Term Trend?

Assessing ProQR Therapeutics NV's (NASDAQ:PRQR) past track record of performance is an insightful exercise for investors. … See our latest analysis for ProQR Therapeutics How Did PRQR's Recent Performance Stack Up Against Its Past? … For the most up-to-date info, I use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data.

Simply Wall St -

Before You Buy ProQR Therapeutics NV's (PRQR), You Should Consider This

Based on this beta value, PRQR appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … How PRQR's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … I test PRQR’s ratio of fixed assets to total assets in order to determine how high the risk is associated with this type of constraint.

Simply Wall St -

Does ProQR Therapeutics NV's (PRQR) CEO Pay Reflect Performance?

See our latest analysis for PRQR What has PRQR performance been like? … Over the last year PRQR delivered negative earnings of -$41M , which is a further decline from prior year's loss of -$33M. … Typically I'd use market cap and profit as factors determining performance, however, PRQR's negative earnings reduces the effectiveness of this method.

Simply Wall St -

Company Info

Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is developing sepofarsen that is in Phase I/II clinical trials for leber’s congenital amaurosis; QR-421a and QR-411 for type 2 usher syndrome; QR-1123 for autosomal dominant retinitis pigmentosa; QR-313 for dystrophic epidermolysis bullosa; and Eluforsen for cystic fibrosis. The company’s stage pipeline products include QR-504 for fuchs endothelial corneal dystrophy; QR-1011 for stargardt’s disease; and QRX-704 for huntington’s disease. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center; and partnership agreement with EB Research Partnership and EB Medical Research Foundation. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.

Details
Name: ProQR Therapeutics N.V.
PRQR
Exchange: NasdaqGM
Founded: 2012
$357,174,032
49,745,687
Website: http://www.proqr.com
Address: ProQR Therapeutics N.V.
Zernikedreef 9,
Leiden,
Zuid-Holland, 2333 Ck,
Netherlands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM PRQR Ordinary Shares Nasdaq Global Market US USD 18. Sep 2014
Number of employees
Current staff
Staff numbers
119
ProQR Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:06
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/18
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.